Biomarin projects 2022 Voxzogo sales of USD 115m

US-based Biomarin brought its dwarfism drug Voxzogo to the market in 2021, and the company has great expectations for the drug in 2022.
Biomarin's Voxzogo is designed to treat achondroplasia, also known as dwarfism | Photo: Anders Rye Skjoldjensen
Biomarin's Voxzogo is designed to treat achondroplasia, also known as dwarfism | Photo: Anders Rye Skjoldjensen
by CHRISTIAN BUNDGAARD, translated by daniel pedersen

US-based biotech firm Biomarin has released its full-year financial report on Wednesday, and in connection with the report came the company’s 2022 sales prognosis for potential cash cow Voxzogo.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading